India set to appeal to WTO over EU seizures of generic drugs

23 April 2010

India will launch a formal dispute against the European Union at the World Trade Organization over EU seizures of Indian generic drugs, said a senior trade ministry source, reported by the Times of India this week.

Settling the dispute could take between 12-18 months, noted another ministry source, who deals directly with WTO issues. India had said it wanted to solve the dispute "amicably" but there has been no breakthrough so far between India and its largest trading partner, the newspaper stated.

"As far as we are concerned, it's a violation of TRIPS [Trade-related Aspects of Intellectual Property Rights] and needs to be taken to the WTO," the senior trade ministry source said, referring to the international trade agreements. "Pharma issue will go to the WTO. India is not satisfied by what is happening in the European Union," the source added. A formal trade dispute has loomed for a long time between India and Brazil on one side and the EU on the other.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK

More ones to watch >